Alumis (ALMS) Non-Current Deferred Tax Liability (2025 - 2026)
Alumis (ALMS) posted quarterly Non-Current Deferred Tax Liability of $2.1 million for Q4 2025, little changed quarter-over-quarter from $2.1 million in Q3 2025.
Powered by 
Analysis
Alumis (ALMS) Non-Current Deferred Tax Liability (2025 - 2026) Analysis & Trends
Alumis (ALMS) has reported Non-Current Deferred Tax Liability for 1 consecutive years, with $2.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability changed N/A year-over-year to $2.1 million; the TTM figure through Dec 2025 stood at $2.1 million (changed N/A YoY), while the FY2025 annual figure was $2.1 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability was little changed at $2.1 million in Q4 2025 per ALMS's latest filing, from $2.1 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $2.1 million in Q2 2025 and bottomed at $2.1 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Alumis | 1.42 Bn | 919.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 383,000.00 |
| Dec 31, 2025 | 2.14 Mn |
| Sep 30, 2025 | 2.14 Mn |
| Jun 30, 2025 | 2.14 Mn |